Stay updated on Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page’s displayed revision/version marker was incremented from v3.5.2 to v3.5.3, reflecting a site release/update rather than a change to the study information.SummaryDifference0.1%

- Check15 days agoChange DetectedRevision tag updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedFooter and policy updates were added, including release notes, privacy and accessibility information, and government links.SummaryDifference100%

- Check43 days agoChange DetectedFooter/navigation items and several archived study documents were removed. The essential trial data remains accessible on the page.SummaryDifference22%

- Check58 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3. No substantive content changes are visible.SummaryDifference0.1%

- Check79 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. No changes to the study details, eligibility criteria, or outcomes were observed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.